FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2267852407> ?p ?o ?g. }

• W2267852407 abstract "Data from post-authorization studies and registries are valuable in establishing the safety and effectiveness of therapies in real-life settings, particularly as physicians may have concerns about the robustness of safety data from randomized controlled trials (RCTs). Furthermore, in routine clinical practice, there may be a potential for increased adverse event reporting with new therapies, and their true safety profile may be difficult to elucidate. The non-vitamin K antagonist (VKA) oral anticoagulant (NOAC) rivaroxaban is a direct factor Xa inhibitor, first approved for the prevention of venous thromboembolism (VTE) following elective hip or knee replacement surgery in 2008, and now licensed for use in five indications in Europe in the venous and arterial thromboembolic space. A number of Phase IV, non-interventional studies, and independent registries are completed or underway that aim to further evaluate safety outcomes with rivaroxaban in everyday clinical practice. These include XAMOS (XArelto in the prophylaxis of post-surgical venous thromboembolism after elective Major Orthopaedic Surgery of the hip or knee), XANTUS (XArelto on preveNtion of sTroke and non-central nervoUS system systemic emboilism in patients with non-valvular atrial fibrillation), and XALIA (XArelto for Long-term and Initial Anticoagulation in venous thromboembolism). Results to date—from XAMOS—show that rivaroxaban has an acceptable safety profile in real-life, with outcomes that are in line with the RECORD (REgulation of Coagulation in ORthopedic surgery to prevent Deep vein thrombosis and pulmonary embolism) clinical trial programme. International and national registries are also gathering information on rivaroxaban and other NOACs. Together, this breadth of studies illustrates an ongoing commitment to understanding real-life outcomes with NOACs." @default.
• W2267852407 created "2016-06-24" @default.
• W2267852407 creator A5004003194 @default.
• W2267852407 creator A5009167101 @default.
• W2267852407 creator A5077297087 @default.
• W2267852407 date "2015-07-01" @default.
• W2267852407 modified "2023-10-06" @default.
• W2267852407 title "Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1" @default.
• W2267852407 cites W1549733185 @default.
• W2267852407 cites W1623587890 @default.
• W2267852407 cites W1832067160 @default.
• W2267852407 cites W1839975480 @default.
• W2267852407 cites W1968492659 @default.
• W2267852407 cites W1973320886 @default.
• W2267852407 cites W1973416160 @default.
• W2267852407 cites W1976152446 @default.
• W2267852407 cites W2001924427 @default.
• W2267852407 cites W2013750247 @default.
• W2267852407 cites W2014491911 @default.
• W2267852407 cites W2014582235 @default.
• W2267852407 cites W2017022669 @default.
• W2267852407 cites W2022932023 @default.
• W2267852407 cites W2036506340 @default.
• W2267852407 cites W2062731392 @default.
• W2267852407 cites W2064385290 @default.
• W2267852407 cites W2074840794 @default.
• W2267852407 cites W2075887313 @default.
• W2267852407 cites W2077033273 @default.
• W2267852407 cites W2089621382 @default.
• W2267852407 cites W2097854437 @default.
• W2267852407 cites W2115787552 @default.
• W2267852407 cites W2118125370 @default.
• W2267852407 cites W2128413398 @default.
• W2267852407 cites W2130199362 @default.
• W2267852407 cites W2134427191 @default.
• W2267852407 cites W2137747726 @default.
• W2267852407 cites W2150567120 @default.
• W2267852407 cites W2151252098 @default.
• W2267852407 cites W2159357148 @default.
• W2267852407 cites W2169793874 @default.
• W2267852407 cites W2171868042 @default.
• W2267852407 cites W2296429742 @default.
• W2267852407 doi "https://doi.org/10.1093/eurheartj/suv038" @default.
• W2267852407 hasPublicationYear "2015" @default.
• W2267852407 type Work @default.
• W2267852407 sameAs 2267852407 @default.
• W2267852407 citedByCount "0" @default.
• W2267852407 crossrefType "journal-article" @default.
• W2267852407 hasAuthorship W2267852407A5004003194 @default.
• W2267852407 hasAuthorship W2267852407A5009167101 @default.
• W2267852407 hasAuthorship W2267852407A5077297087 @default.
• W2267852407 hasBestOaLocation W22678524071 @default.
• W2267852407 hasConcept C126322002 @default.
• W2267852407 hasConcept C127413603 @default.
• W2267852407 hasConcept C141071460 @default.
• W2267852407 hasConcept C177713679 @default.
• W2267852407 hasConcept C197934379 @default.
• W2267852407 hasConcept C2776265017 @default.
• W2267852407 hasConcept C2776301958 @default.
• W2267852407 hasConcept C2776704044 @default.
• W2267852407 hasConcept C2778661090 @default.
• W2267852407 hasConcept C2778959117 @default.
• W2267852407 hasConcept C2779161974 @default.
• W2267852407 hasConcept C2780645631 @default.
• W2267852407 hasConcept C2780868729 @default.
• W2267852407 hasConcept C535046627 @default.
• W2267852407 hasConcept C71924100 @default.
• W2267852407 hasConcept C78519656 @default.
• W2267852407 hasConceptScore W2267852407C126322002 @default.
• W2267852407 hasConceptScore W2267852407C127413603 @default.
• W2267852407 hasConceptScore W2267852407C141071460 @default.
• W2267852407 hasConceptScore W2267852407C177713679 @default.
• W2267852407 hasConceptScore W2267852407C197934379 @default.
• W2267852407 hasConceptScore W2267852407C2776265017 @default.
• W2267852407 hasConceptScore W2267852407C2776301958 @default.
• W2267852407 hasConceptScore W2267852407C2776704044 @default.
• W2267852407 hasConceptScore W2267852407C2778661090 @default.
• W2267852407 hasConceptScore W2267852407C2778959117 @default.
• W2267852407 hasConceptScore W2267852407C2779161974 @default.
• W2267852407 hasConceptScore W2267852407C2780645631 @default.
• W2267852407 hasConceptScore W2267852407C2780868729 @default.
• W2267852407 hasConceptScore W2267852407C535046627 @default.
• W2267852407 hasConceptScore W2267852407C71924100 @default.
• W2267852407 hasConceptScore W2267852407C78519656 @default.
• W2267852407 hasLocation W22678524071 @default.
• W2267852407 hasOpenAccess W2267852407 @default.
• W2267852407 hasPrimaryLocation W22678524071 @default.
• W2267852407 hasRelatedWork W1970392557 @default.
• W2267852407 hasRelatedWork W2051099832 @default.
• W2267852407 hasRelatedWork W2061715561 @default.
• W2267852407 hasRelatedWork W2076611022 @default.
• W2267852407 hasRelatedWork W2085177779 @default.
• W2267852407 hasRelatedWork W2094111814 @default.
• W2267852407 hasRelatedWork W2280135102 @default.
• W2267852407 hasRelatedWork W2320488900 @default.
• W2267852407 hasRelatedWork W2346289199 @default.
• W2267852407 hasRelatedWork W2586002753 @default.
• W2267852407 hasRelatedWork W2606280557 @default.
• W2267852407 hasRelatedWork W2622489359 @default.
• W2267852407 hasRelatedWork W2792139659 @default.

• next